Ofatumumab

Therapeutic indications

Ofatumumab is indicated for:

Chronic lymphocytic leukaemia (CLL)

Population group: only adults (18 years old or older)

Previously untreated chronic lymphocytic leukaemia (CLL)

Ofatumumab in combination with chlorambucil or bendamustine is indicated for the treatment of adult patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.

Relapsed CLL

Ofatumumab is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed CLL.

Refractory CLL

Ofatumumab is indicated for the treatment of CLL in adult patients who are refractory to fludarabine and alemtuzumab.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: ARZERRA Concentrate for solution for infusion
Summary of Product Characteristics (SPC) 2021: KESIMPTA Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈